GIST a rare abdominal tumor and our surgical experience
DOI:
https://doi.org/10.18203/2320-6012.ijrms20222527Keywords:
CD117, Gastrointestinal stromal tumours, Imatinib, Interstitial cells of CajalAbstract
Background: GISTs are rare abdominal tumors, encountered as the most common mesenchymal neoplasms of the gastrointestinal (GI) tract leading to GI bleeding. We report a changing trend of diagnosis and management in Indian patients.
Methods: The retrospective data was collected from medical records and 62 cases of GIST from 2003 to 2020 in General surgical unit of BHU. They were divided in three groups. In group A (36) patients only surgery, group B (14) patients surgery than adjuvant chemotherapy and in group C (12) who received neoadjuvant chemotherapy then surgery. Preoperatively, USG and CT scans of the abdomen were the main investigations, others being upper gastrointestinal endoscopy and chest x-ray confirm by histopathological and immunohistochemical evaluation.
Results: The mean age at presentation was 42.8 years (range 17-74 years) and mean duration of symptoms was of 5 months (range 10 days-2 years). It was from the stomach, (06) duodenum (14) jejunum, (06) ileum, (1) caecum and (4) from the mesentery and (4) from retroperitoneum. 44 cases had low grade benign tumors and 18 malignancies. In group A, 22 (61%) patients showed recurrence in group B, 06, (42%) patients showed recurrence and group C, 02 (33%) patient showed recurrence.
Conclusions: Most of the tumours were benign and surgical resection is the mainstay of treatment. However, the patients in which only surgery was done showed maximum recurrence and patients who received neoadjuvant chemotherapy then surgery followed adjuvant chemotherapy showed minimum recurrence.
References
Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumours. J Clin Oncol. 2004;22:3813-25.
Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumour (GIPACT): gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259-69.
Miettinen M, Lasota J. Gastrointestinal stromal tumours- definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1-12.
Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumours: a consensus approach. Hum Pathol. 2002;33:459-65.
Joensuu H. Gastrointestinal stromal tumour (GIST). Ann Oncol. 2006;17:280-6.
Pappo AS, Janeway KA. Pediatric gastrointestinal stromal tumours. Hematol Oncol Clin North Am. 2009;23:15-34.
Katz SC, DeMatteo RP. Gastrointestinal Stromal Tumours and Leiomyosarcomas. J of Surg Oncol. 2008;97:350-9.
Kumar P, Agrawal A, Shah AK, Gambhir RPS, Galagali A, Chaudhry R. Gastrointestinal stromal tumours: Our experience. Indian J Surg. 2010;72:112-6.
Everett M, Gutman H. Surgical management of gastrointestinal stromal tumours: analysis of outcome with respect to surgical margins and technique. J Surg Oncol. 2008;98:588-93.
Hashiba T, Oda K, Koda K, Takiguchi N, Seike K, Miyazaki M. A gastrointestinal stromal tumour in the stomach: usefulness of computerized tomography volumetry. Gastric Cancer. 2004;7:260-5.
Rubin BP, Blanke CD, Demetri GD, Dematteo RP, Fletcher CD, Goldblum JR, et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumour. Arch Pathol Lab Med. 2010;134:165-70.
Annaberdyev S, Gibbons J, Hardacre JM. Dramatic response of a gastrointestinal stromal tumour to neoadjuvant Imatinib therapy. World J Surg Oncol. 2009;7:30.
West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG-1, is expressed ubiquitously in gastrointestinal stromal tumours irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107-13.
Belev B, Brcic I, Prejac J, Golubic ZA, Vrbanec D, Bozikov J, et al. Role of Ki-67as a prognostic factor in gastrointestinal stromal tumours. World J Gastroenterol. 2013;28;19(4):523-7.
Kosmadakis N, Visvardis EE, Kartsaklis P, Tsimara M, Chatziantoniou A, Panopoulos I, et al. The role of surgery in the management of gastrointestinal stromal tumours in the era of imatinib mesylate effectiveness. Surg Oncol. 2005;14:75-84.
Von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, et al. Gastrointestinal stromal tumours, version 2.2014. J Nat Compr Canc Netw. 2014;12(6):853-62.
Chiappa A, Zbar AP, Innis M, Garriques S, Bertani E, Biffi R, et al. Prognostic factors affecting survival after surgical resection of gastrointestinal stromal tumours: A two-unit experience over ten years. World J Surg Oncol. 2006;4:73.
Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: The ESMO/ European Sarcoma Network Working Group. Ann Oncol. 2012;23(7):vii49-55.
Gastrointestinal Stromal Tumour Meta Analysis Group (MetaGIST). Comparison of two doses of Imatinib for the treatment of un resectable or metastatic gastrointestinal stromal tumours: a meta analysis of 1,640 patients. J Clin Oncol. 2010;28:1247-53.
Demetri GD, Van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of Imatinib: A randomised controlled trial. Lancet. 2006;368:1329-38.
Arolfo S, Teggia PM, Nano M. Gastrointestinal stromal tumours: Thirty years’ experience of an institution. World J Gastroenterol. 2011;17:1836-9.
